Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Abacavir
Drug ID BADD_D00008
Description Abacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. In vivo, abacavir sulfate dissociates to its free base, abacavir.
Indications and Usage For the treatment of HIV-1 infection, in combination with other antiretroviral agents.
Marketing Status approved; investigational
ATC Code J05AF06
DrugBank ID DB01048
KEGG ID D07057
MeSH ID C106538
PubChem ID 441300
TTD Drug ID D0A4IJ
NDC Product Code 55111-920; 72865-167; 50268-049; 31722-562; 70518-1274; 65862-073; 31722-557; 68084-021; 0904-6874; 64380-717; 69097-514
UNII WR2TIP26VS
Synonyms abacavir | 1592U89 | abacavir sulfate | Ziagen | (1S,4R)-4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene-1-methanol | abacavir succinate
Chemical Information
Molecular Formula C14H18N6O
CAS Registry Number 136470-78-5
SMILES C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)C4CC(C=C4)CO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypercholesterolaemia14.08.01.001---
Hyperglycaemia05.06.02.002; 14.06.02.002--
Hyperlactacidaemia14.01.01.006---
Hypersensitivity10.01.03.0030.016485%
Hypertriglyceridaemia14.08.02.001--
Hypotension24.06.03.002--
Influenza like illness08.01.03.010--
Insomnia17.15.03.002; 19.02.01.002--
Insulin resistance05.06.02.003; 14.06.02.003---
Lactic acidosis14.01.01.0020.006182%-
Lethargy08.01.01.008; 17.02.04.003; 19.04.04.004--
Leukopenia01.02.02.001---
Liver function test abnormal13.03.04.030---
Lymphadenopathy01.09.01.0020.006182%-
Lymphopenia01.02.02.002---
Malaise08.01.01.0030.011128%
Migraine17.14.02.001; 24.03.05.003---
Mouth ulceration07.05.06.004---
Muscle spasms15.05.03.0040.009067%
Muscular weakness15.05.06.001; 17.05.03.005--
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.0010.006182%
Myocardial infarction02.02.02.007; 24.04.04.0090.008243%
Myocardial ischaemia02.02.02.008; 24.04.04.0100.004121%-
Nausea07.01.07.0010.012364%
Nervous system disorder17.02.10.001---
Neuropathy peripheral17.09.03.003---
Neutropenia01.02.03.004---
Oedema08.01.07.006; 14.05.06.010---
Opportunistic infection11.01.08.007---
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene